The Utah House Feb. 19 passed a bill (H.B. 94) allowing terminally ill patients to gain access to investigational drugs and devices.
The House approved the “Utah Right to Try Act” on a 72-1 third reading vote and sent it to the Senate. It would allow terminally ill patients to work with their doctors or directly with drug and device manufacturers to gain access to therapies that have passed phase I clinical trials but haven’t been fully approved by the Food and Drug Administration for use. On Feb. 23, the legislation was sent to the Senate Health and Human Services ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.